U.S. Markets closed

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,615.00-10.00 (-0.62%)
At close: 4:35PM BST
Full screen
Previous Close1,625.00
Bid1,605.00 x 175400
Ask1,640.00 x 417900
Day's Range1,614.50 - 1,632.00
52 Week Range1,446.50 - 1,745.56
Avg. Volume8,028,178
Market Cap78.9B
PE Ratio (TTM)47.36
Earnings DateN/A
Dividend & Yield1.00 (4.66%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
  • Reuters9 hours ago

    GlaxoSmithKline's new CEO prepares to trim drug pipeline

    GlaxoSmithKline's new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company's pipeline of new drugs. Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain's biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.

  • These Non-Tech Firms Are Making Big Bets On Artificial Intelligence
    Investor's Business Dailyyesterday

    These Non-Tech Firms Are Making Big Bets On Artificial Intelligence

    Loup Ventures has compiled a portfolio of 17 publicly traded non-tech companies that are making investments in artificial intelligence to improve their businesses.

  • American City Business Journalsyesterday

    Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million

    Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately. On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal came less than a week after Emergent (EBS) announced it would buy French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million.